InsightSphere

Anthropic Signs $35 Billion Cloud Deal With Nvidia-Backed Lambda

Anthropic's $35 billion cloud deal with Nvidia-backed Lambda gives the AI company long-term access to computing power for Claude and Claude Code as demand grows. The agreement centers on a 350-megawatt data center in Nueces County, Texas, built by Hut 8 and reportedly leased directly by Nvidia. This article breaks down how the deal works, why it follows Anthropic's recent $45 billion scale agreement, and what Nvidia's expanding role across chips, capital, and leases means for the AI industry. Keep reading to understand why compute access is becoming as important as model performance.

Singapore Expands Tax Incentives for Fund Managers After Hong Kong Competition

China's First Humanoid Robot IPO Ignites an Investor Frenzy

Unitree Robotics just became the first humanoid robot maker to list on mainland China's stock market, and its shares jumped more than 460% on the very first day of trading in Shanghai. That kind of reaction tells you investors are starting to treat humanoid robots as a real business opportunity, not just a flashy tech demo. This article breaks down how Unitree built its lead in the market, why its robots cost so much less than American competitors like Boston Dynamics, and how rising tension between the US and China over robot imports could shape what comes next. Keep reading to see what this IPO really means for the industry.

Unitree Founder Predicts Robots Will Reach the Mass Market Within a Decade

Moderna's mRNA Flu Vaccine Wins US FDA Approval in Major Breakthrough

Exclusive

Moderna's mRNA flu vaccine, mFlusiva, has just received FDA approval, making it the first messenger RNA shot cleared for seasonal flu in the U.S. Adults aged 50 to 64 get full approval, while those 65 and older are covered under accelerated approval as more data comes in. This article breaks down how the vaccine works, why it outperformed a standard flu shot in trials, and what it means for rivals like Sanofi and GSK. It also looks at how this approval could reshape Moderna's business and where vaccine technology may be headed next. Read on for the full story.

GSK to Buy Nuvalent for $10.6 Billion to Expand in Cancer Drugs

Automotive

Toyota Unveils $6.3 Billion Buyback, Raises Profit Outlook

Toyota just rolled out a $6.3 billion share buyback and, at the same time, raised its profit outlook for the year, even though the company is now sitting on its fifth straight quarter of falling profit. This article breaks down why Toyota is choosing to reward shareholders right now, despite weak sales in China and rising costs tied to the Iran war. You'll see how a weaker yen helped boost Toyota's full-year forecast, why the company lowered its estimate of war-related costs, and what the recent earthquake in Kyushu could mean for production down the road. Keep reading for a closer look at Toyota's earnings, its buyback plan, and what this all means for the wider auto industry.

War Rewrites the Energy Equation for Indonesia and Beyond

Global Aluminum Rally Could Draw Record Exports From China

The Global Aluminum Rally is no longer just a pricing story. It is quickly becoming a trade story, and the momentum behind it is hard to ignore. The gap between what aluminium fetches on the London Metal Exchange and what it commands inside China has stretched to its widest point in over three years. That kind of divergence does not sit idle for long. Producers on the Chinese side of that equation are already responding, and if early shipment trends are any indication, the world could be looking at record Chinese aluminium exports before the year is out. What began as a market reaction to a regional crisis is steadily taking on a life of its own.